Find, compare & contact
Taspoglutide
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Taspoglutide API 275371-94-3?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Taspoglutide. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Taspoglutide
- Synonyms:
- Taspoglutida , Taspoglutidum
- Cas Number:
- 275371-94-3
- DrugBank number:
- DB14027
- Unique Ingredient Identifier:
- 2PHK27IP3B
General Description:
Taspoglutide, identified by CAS number 275371-94-3, is a notable compound with significant therapeutic applications. Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects. As of May 2013 no new trials had been registered.
Categories:
Taspoglutide is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Blood Glucose Lowering Agents, Gastrointestinal Hormones, GLP-1 Agonists, Glucagon-Like Peptides, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Proglucagon. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Taspoglutide is a type of Hormonal Agents
Hormonal agents are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the medical field. These substances play a crucial role in regulating and modulating hormonal functions within the body. Hormonal agents are designed to mimic or manipulate the effects of naturally occurring hormones, allowing healthcare professionals to treat various endocrine disorders and hormonal imbalances.
Hormonal agents are commonly employed in the treatment of conditions such as hypothyroidism, hyperthyroidism, diabetes, and hormonal cancers. These APIs work by interacting with specific hormone receptors, either by stimulating or inhibiting their activity, to restore the balance of hormones in the body. They can be administered orally, intravenously, or through other routes depending on the specific medication and patient needs.
Pharmaceutical companies employ rigorous manufacturing processes and quality control measures to ensure the purity, potency, and safety of hormonal agent APIs. These APIs are synthesized using chemical or biotechnological methods, often starting from natural hormone sources or through recombinant DNA technology. Stringent regulatory guidelines are in place to guarantee the efficacy and safety of hormonal agent APIs, ensuring that patients receive high-quality medications.
As the demand for hormone-related therapies continues to grow, ongoing research and development efforts focus on enhancing the effectiveness and reducing the side effects of hormonal agent APIs. This includes the exploration of novel delivery systems, advanced formulations, and targeted drug delivery methods. By continuously advancing our understanding and capabilities in hormonal agents, the medical community can improve patient outcomes and quality of life for individuals with hormonal disorders.
